NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients

Intermediate-risk acute myeloid leukemia (IR-AML) is the largest subgroup of AML patients and is highly heterogeneous. Whereas adverse and favourable risk patients have well-established treatment protocols, IR-AML patients have not. It is, therefore, crucial to find novel factors that stratify this subgroup to implement risk-adapted strategies. The CAS (Crk-associated substrate) adaptor protein family regulates cell proliferation, survival, migration and adhesion. Despite its association with metastatic dissemination and prognosis of different solid tumors, the role of these proteins in hematological malignancies has been scarcely evaluated. Nevertheless, previous work has established an important role for the CAS family members NEDD9 or BCAR1 in the migratory and dissemination capacities of myeloid cells. On this basis, we hypothesized that NEDD9 or BCAR1 expression levels could associate with survival in IR-AML patients and become new prognostic markers. To that purpose, we assessed BCAR1 and NEDD9 gene expression in a cohort of 73 adult AML patients validating the results in an independent cohort (n = 206). We have identified NEDD9, but not BCAR1, as a new a marker for longer overall and disease-free survival, and for lower cumulative incidence of relapse. In summary, NEDD9 gene expression is an independent prognostic factor for favourable prognosis in IR-AML patients.

[1]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[2]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[3]  W. Hogan,et al.  Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. , 2015, Leukemia research.

[4]  N. Bailey,et al.  Acute Myeloid Leukemia Genetics: Risk Stratification and Implications for Therapy. , 2015, Archives of pathology & laboratory medicine.

[5]  Li Yu,et al.  Genomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid Leukemia , 2015, Chinese medical journal.

[6]  A. Gaponova,et al.  Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases. , 2015, Gene.

[7]  A. Reinisch,et al.  Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. , 2015, Seminars in hematology.

[8]  K. Döhner,et al.  Intermediate-risk acute myeloid leukemia therapy: current and future. , 2014, Hematology. American Society of Hematology. Education Program.

[9]  A. Gaponova,et al.  CAS proteins in health and disease: An update , 2014, IUBMB life.

[10]  M. Minden,et al.  The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics , 2013, Blood Cancer Journal.

[11]  J. Esteve,et al.  Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. , 2013, Blood.

[12]  J. Parsons,et al.  Cas and NEDD9 Contribute to Tumor Progression through Dynamic Regulation of the Cytoskeleton. , 2012, Genes & cancer.

[13]  B. Fabry,et al.  NEDD9 Stabilizes Focal Adhesions, Increases Binding to the Extra-Cellular Matrix and Differentially Effects 2D versus 3D Cell Migration , 2012, PloS one.

[14]  C. Marshall,et al.  The metastasis gene NEDD9 product acts through integrin β3 and Src to promote mesenchymal motility and inhibit amoeboid motility , 2012, Journal of Cell Science.

[15]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[16]  Jun Lu,et al.  Crk‐associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl , 2011, Cancer science.

[17]  Shan Zhu,et al.  NEDD9 Is a Positive Regulator of Epithelial-Mesenchymal Transition and Promotes Invasion in Aggressive Breast Cancer , 2011, PloS one.

[18]  Jasmin H. Bavarva,et al.  HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression , 2011, Oncogene.

[19]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[20]  R. Hills,et al.  Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Sun-Hee Kim,et al.  Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells. , 2010, Cancer research.

[22]  E. Golemis,et al.  CAS proteins in normal and pathological cell growth control , 2010, Cellular and Molecular Life Sciences.

[23]  W. Sauerbrei,et al.  Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines , 2009, British Journal of Cancer.

[24]  M. Wolfson,et al.  NEDD9 promotes oncogenic signaling in mammary tumor development. , 2009, Cancer research.

[25]  N. Nadal,et al.  Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. , 2009, Leukemia research.

[26]  R. Sakai,et al.  Expression and tyrosine phosphorylation of Crk‐associated substrate lymphocyte type (Cas‐L) protein in human neutrophils , 2008, Journal of cellular biochemistry.

[27]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[28]  G. O'Neill,et al.  A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. , 2007, Cancer research.

[29]  G. O'Neill,et al.  Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle , 2007, Cell Biochemistry and Biophysics.

[30]  S. Ogawa,et al.  Crk-Associated Substrate Lymphocyte Type Is Required for Lymphocyte Trafficking and Marginal Zone B Cell Maintenance1 , 2005, The Journal of Immunology.

[31]  for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[32]  S. Iwata,et al.  HTLV-I Tax induces and associates with Crk-associated substrate lymphocyte type (Cas-L) , 2005, Oncogene.

[33]  J. Ruidavets,et al.  Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. , 2004, Cancer research.

[34]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[35]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[36]  N. Heisterkamp,et al.  BCR/ABL-induced Leukemogenesis Causes Phosphorylation of Hef1 and Its Association with Crkl* , 1997, The Journal of Biological Chemistry.

[37]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[38]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[39]  N. Villamor,et al.  Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)] , 2006, Leukemia.

[40]  W. Sauerbrei,et al.  REporting recommendations for tumor MARKer prognostic studies (REMARK). , 2005, Nature clinical practice. Oncology.

[41]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[42]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[43]  Thomas D. Schmittgen,et al.  Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method , 2022 .